高级检索
当前位置: 首页 > 详情页

N6-Methyladenosine-Related lncRNAs Are Anticipated Biomarkers for Sarcoma Patients

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Orthoped, Nanjing 210003, Jiangsu, Peoples R China [2]Sun Yat sen Univ, Affiliated Hosp 1, Dept Musculoskeletal Oncol, Guangzhou 510080, Guangdong, Peoples R China [3]Zhejiang Univ, Affiliated Hosp 2, Dept Surg, Sch Med, Hangzhou 310009, Zhejiang, Peoples R China [4]Eastern Theater Gen Hosp Qinhuai Dist Med Area, Dept Neurol, Nanjing 210000, Jiangsu, Peoples R China
出处:
ISSN:

摘要:
Background. Soft tissue sarcomas (STSs) are rare tumors and occur at any site in the body. Our goal was to identify a putative molecular mechanism for N6-methyladenosine (m6A) lncRNA alteration and to develop predictive biomarkers for sarcoma. Methods. The lncRNA levels were obtained from TCGA datasets. Pearson correlation analysis was used to select all the lncRNAs that are connected to m6A. An m6A-related lncRNA model was built using LASSO Cox regression. To assess the prognostic efficiency of the model and potential lncRNAs, we performed univariate survival analysis and receiver operating characteristic (ROC) analysis. We also performed enrichment analysis to evaluate the roles of the potential genes. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to confirm m6A-related lncRNA expression in tissues. Results. Following Pearson correlation analysis on TCGA datasets, we identified 78 m6A-related lncRNAs. Next, we used LASSO Cox regression analysis and identified 13 m6A-related lncRNAs as prognostic lncRNAs. After calculating risk scores, sarcoma patients were divided into high- and low-risk groups depending on the median of risk scores. We also found that these lncRNAs were immune associated via enrichment analysis. Conclusions. Here, we found that SNHG1, FIRRE, and YEATS2-AS1 could serve as biomarkers to predict overall survival of sarcoma patients, which provides a new insight into treatment of STS.

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 4 区 肿瘤学
最新[2025]版:
JCR分区:
出版当年[2020]版:
Q2 ONCOLOGY
最新[2023]版:

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Nanjing Univ Chinese Med, Hosp Nanjing 2, Dept Orthoped, Nanjing 210003, Jiangsu, Peoples R China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2022 今日访问量:0 总访问量:648 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号